Mabion SA

WAR:MAB (Poland)  
zł 16.66 (-1.42%) May 29
6.59
P/B:
2.04
Market Cap:
zł 269.26M ($ 67.90M)
Enterprise V:
zł 244.70M ($ 61.71M)
Volume:
32.17K
Avg Vol (2M):
40.83K
Warning! GuruFocus detected 3 Severe warning signs with MAB. Try a 7-Day Free Trial to check it out.
Also Trade In:
Volume:
32.17K
Market Cap zł:
269.26M
Market Cap $:
67.90M
6.59
Avg Vol (2M):
40.83K
Enterprise Value zł:
244.70M
Enterprise Value $:
61.71M
PB Ratio:
2.04
Alerts Website Sources Stock PDF
Dataset
Financial Download P Manual of Stocksâ„¢

Business Description

Mabion SA
NAICS : 325412 SIC : 2833
ISIN : PLMBION00016
https://www.mabion.eu
ul. Gen. Mariana Langiewicza 60, Konstantynow Lodzki, POL, 95-050
Compare
Compare
WAR:PTGWAR:BCXWAR:MOCWAR:BIOWAR:SVEWAR:URTWAR:CTXWAR:PHRWAR:PURWAR:RDGOCSE:NOVO BVRTXREGNASX:CSLSGENXKRX:207940MRNAHKSE:02269XBRU:ARGXBNTX
Traded in other countries / regions
MAB.Poland272.Germany0QGW.UK
IPO Date
2010-08-10
Description
Mabion SA is a Polish biotechnology company focused on developing and launching modern biotechnology drugs based on monoclonal antibody technology. The drugs developed by the company are targeted treatments, characterized by the drug's ability to recognize the factor causing cancer and interact with this factor only. The company is working on the development of its main priority drug, referred to as the MabionCD20 drug. The therapeutic uses of MabionCD20 are for Non-Hodgkin's lymphoma, Leukemia, and Rheumatoid Arthritis.

Financials

WAR:MAB's 30-Y Financials
AAPL
Income Statement Breakdown FY
No Enough Data
AAPL
Balance Sheet Breakdown
No Enough Data
AAPL
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Mabion SA Executives

Details

GF Value: zł18.99

WAR:MAB

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil zł) 146.106
EPS (TTM) (zł) 2.59
Beta 2.21
Volatility % 34.24
14-Day RSI 41.51
14-Day ATR (zł) 0.632594
20-Day SMA (zł) 17.433
12-1 Month Momentum % -8.82
52-Week Range (zł) 15.5 - 23.6
Shares Outstanding (Mil) 16.16

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 6
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Mabion SA Filings

Filing Date Document Date Form
No Filing Data

Mabion SA Stock Events

Financials Calendars
Event Date Price(zł)
No Event Data

Mabion SA Frequently Asked Questions

What is Mabion SA(WAR:MAB)'s stock price today?
The current price of WAR:MAB is zł16.66. The 52 week high of WAR:MAB is zł23.60 and 52 week low is zł15.50.
When is next earnings date of Mabion SA(WAR:MAB)?
The next earnings date of Mabion SA(WAR:MAB) is .
Does Mabion SA(WAR:MAB) pay dividends? If so, how much?
Mabion SA(WAR:MAB) does not pay dividend.

Press Release

Subject Date
No Press Release
Research Tools
All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board
Product
Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文
Education
Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation
Company
About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program
Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey
Follow Us
download GuruFocus on Apple store download GuruFocus on Google Play
Disclaimers
GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.
© 2004-2024 GuruFocus.com, LLC. All Rights Reserved.